Literature DB >> 26176846

Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice.

R W Gould, D Dencker1, M Grannan, M Bubser, X Zhan, J Wess2, Z Xiang, C Locuson, C W Lindsley, P J Conn, C K Jones.   

Abstract

The M1 muscarinic acetylcholine receptor (mAChR) subtype has been implicated in the underlying mechanisms of learning and memory and represents an important potential pharmacotherapeutic target for the cognitive impairments observed in neuropsychiatric disorders such as schizophrenia. Patients with schizophrenia show impairments in top-down processing involving conflict between sensory-driven and goal-oriented processes that can be modeled in preclinical studies using touchscreen-based cognition tasks. The present studies used a touchscreen visual pairwise discrimination task in which mice discriminated between a less salient and a more salient stimulus to assess the influence of the M1 mAChR on top-down processing. M1 mAChR knockout (M1 KO) mice showed a slower rate of learning, evidenced by slower increases in accuracy over 12 consecutive days, and required more days to acquire (achieve 80% accuracy) this discrimination task compared to wild-type mice. In addition, the M1 positive allosteric modulator BQCA enhanced the rate of learning this discrimination in wild-type, but not in M1 KO, mice when BQCA was administered daily prior to testing over 12 consecutive days. Importantly, in discriminations between stimuli of equal salience, M1 KO mice did not show impaired acquisition and BQCA did not affect the rate of learning or acquisition in wild-type mice. These studies are the first to demonstrate performance deficits in M1 KO mice using touchscreen cognitive assessments and enhanced rate of learning and acquisition in wild-type mice through M1 mAChR potentiation when the touchscreen discrimination task involves top-down processing. Taken together, these findings provide further support for M1 potentiation as a potential treatment for the cognitive symptoms associated with schizophrenia.

Entities:  

Keywords:  BQCA; M1 knockout mice; M1 muscarinic acetylcholine receptors; Positive allosteric modulators; top-down processing; touchscreen cognition

Mesh:

Substances:

Year:  2015        PMID: 26176846      PMCID: PMC4830475          DOI: 10.1021/acschemneuro.5b00123

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  65 in total

1.  Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice.

Authors:  Stephan G Anagnostaras; Geoffrey G Murphy; Susan E Hamilton; Scott L Mitchell; Nancy P Rahnama; Neil M Nathanson; Alcino J Silva
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

Review 2.  Direct and indirect modulation of the N-methyl D-aspartate receptor.

Authors:  M J Marino; P Jeffrey Conn
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-02

3.  Impaired control of visual attention in schizophrenia.

Authors:  Rebecca L Fuller; Steven J Luck; Elsie L Braun; Benjamin M Robinson; Robert P McMahon; James M Gold
Journal:  J Abnorm Psychol       Date:  2006-05

Review 4.  The muscarinic system, cognition and schizophrenia.

Authors:  Sean P Carruthers; Caroline T Gurvich; Susan L Rossell
Journal:  Neurosci Biobehav Rev       Date:  2015-05-21       Impact factor: 8.989

Review 5.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

6.  Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  B Dean; M McLeod; D Keriakous; J McKenzie; E Scarr
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

7.  Impaired hierarchical control within the lateral prefrontal cortex in schizophrenia.

Authors:  Guillaume Barbalat; Valerian Chambon; Philippe J D Domenech; Chrystèle Ody; Etienne Koechlin; Nicolas Franck; Chlöé Farrer
Journal:  Biol Psychiatry       Date:  2011-04-09       Impact factor: 13.382

8.  The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli.

Authors:  J C Talpos; A C Fletcher; C Circelli; M D Tricklebank; S L Dix
Journal:  Psychopharmacology (Berl)       Date:  2011-11-26       Impact factor: 4.530

Review 9.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

Review 10.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

View more
  26 in total

Review 1.  The Role of Estrogen in Brain and Cognitive Aging.

Authors:  Jason K Russell; Carrie K Jones; Paul A Newhouse
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 2.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

3.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; Shahnawaz M Amdani; Zhenglan Chen; Ren-Qi Huang; John A Schetz
Journal:  Pharmacol Res       Date:  2016-05-06       Impact factor: 7.658

Review 4.  Physiological roles of CNS muscarinic receptors gained from knockout mice.

Authors:  Morgane Thomsen; Gunnar Sørensen; Ditte Dencker
Journal:  Neuropharmacology       Date:  2017-09-11       Impact factor: 5.250

Review 5.  Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Authors:  Daniel J Foster; P Jeffrey Conn
Journal:  Neuron       Date:  2017-05-03       Impact factor: 17.173

Review 6.  Advances in Drug Discovery and Development in Geriatric Psychiatry.

Authors:  Alexander C Conley; Paul A Newhouse
Journal:  Curr Psychiatry Rep       Date:  2018-03-05       Impact factor: 5.285

7.  PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems.

Authors:  Sean P Moran; Hyekyung P Cho; James Maksymetz; Daniel H Remke; Ryan M Hanson; Colleen M Niswender; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-04-25       Impact factor: 4.418

8.  Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress.

Authors:  Max E Joffe; Chiaki I Santiago; Branden J Stansley; James Maksymetz; Rocco G Gogliotti; Julie L Engers; Ferdinando Nicoletti; Craig W Lindsley; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2018-10-13       Impact factor: 5.250

Review 9.  Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline.

Authors:  Elizabeth C Ballinger; Mala Ananth; David A Talmage; Lorna W Role
Journal:  Neuron       Date:  2016-09-21       Impact factor: 17.173

10.  Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.

Authors:  Michael D Grannan; Catharine A Mielnik; Sean P Moran; Robert W Gould; Jacob Ball; Zhuoyan Lu; Michael Bubser; Amy J Ramsey; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2016-10-05       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.